| 2025-11-04 |
详情>>
股本变动：
变动后总股本176738.46万股
|
| 2025-11-04 |
详情>>
业绩披露：
2025年三季报(累计)每股收益1.35美元,归母净利润23.80亿美元,同比去年增长-44.65%
|
| 2025-10-31 |
财报披露：
美东时间 2025-10-31 盘前发布财报
|
| 2025-08-12 |
详情>>
内部人交易：
SALEKI-GERHARDT AZITA共交易2笔
|
| 2025-08-04 |
详情>>
业绩披露：
2025年中报每股收益1.25美元,归母净利润22.24亿美元,同比去年增长-18.21%
|
| 2025-05-09 |
详情>>
业绩披露：
2025年一季报每股收益0.72美元,归母净利润12.76亿美元,同比去年增长-6.11%
|
| 2025-03-24 |
股东大会：
将于2025-05-09召开股东大会
会议内容 ▼▲
- 1.To elect four directors to hold office until the 2028 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2025.
3.To vote on an advisory basis on the approval of executive compensation.
4.To vote on a management proposal to eliminate supermajority voting.
5.To consider any other matters that may properly come before the meeting, including one stockholder proposal, if presented during the meeting.
|
| 2025-02-14 |
详情>>
业绩披露：
2022年年报每股收益6.65美元,归母净利润118.36亿美元,同比去年增长3.21%
|
| 2025-02-14 |
详情>>
业绩披露：
2024年年报每股收益2.40美元,归母净利润42.78亿美元,同比去年增长-11.24%
|
| 2024-11-04 |
详情>>
业绩披露：
2024年三季报(累计)每股收益2.41美元,归母净利润43.00亿美元,同比去年增长7.26%
|
| 2024-08-07 |
详情>>
业绩披露：
2024年中报每股收益1.54美元,归母净利润27.19亿美元,同比去年增长21.33%
|
| 2024-05-03 |
详情>>
业绩披露：
2024年一季报每股收益0.77美元,归母净利润13.59亿美元,同比去年增长496.05%
|
| 2024-03-18 |
股东大会：
将于2024-05-03召开股东大会
会议内容 ▼▲
- 1.To elect five directors to hold office until the 2027 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2024.
3.To vote on an advisory basis on the approval of executive compensation.
4.To vote on an advisory basis on the frequency of future stockholder advisory votes on executive compensation.
5.To vote on a management proposal to eliminate supermajority voting.
6.To consider any other matters that may properly come before the meeting, including three stockholder proposals, if presented during the meeting.
|
| 2024-02-20 |
详情>>
业绩披露：
2023年年报每股收益2.73美元,归母净利润48.20亿美元,同比去年增长-59.28%
|
| 2023-11-06 |
详情>>
业绩披露：
2023年三季报(累计)每股收益2.27美元,归母净利润40.09亿美元,同比去年增长-56.98%
|
| 2023-03-20 |
股东大会：
将于2023-05-05召开股东大会
会议内容 ▼▲
- 1.To elect three directors to hold office until the 2026 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023.
3.To vote on an advisory basis on the approval of executive compensation.
4.To vote on a management proposal to eliminate supermajority voting.
5.To consider any other matters that may properly come before the meeting, including four stockholder proposals, if presented during the meeting.
|
| 2023-03-20 |
股东大会：
将于2023-05-05召开股东大会
会议内容 ▼▲
- 1.To elect three directors to hold office until the 2026 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2023.
3.To vote on an advisory basis on the approval of executive compensation.
4.To vote on a management proposal to eliminate supermajority voting.
5.To consider any other matters that may properly come before the meeting, including four stockholder proposals, if presented during the meeting.
|
| 2022-03-21 |
股东大会：
将于2022-05-06召开股东大会
会议内容 ▼▲
- 1.To elect four directors to hold office until the 2025 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2022.
3.To vote on an advisory basis on the approval of executive compensation.
4.To vote on a management proposal to eliminate supermajority voting.
5.To consider any other matters that may properly come before the meeting, including four stockholder proposals, if presented during the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-03-22 |
股东大会：
将于2021-05-07召开股东大会
会议内容 ▼▲
- 1.To elect four directors to hold office until the 2024 Annual Meeting or until their successors are elected.
2.To ratify the appointment of Ernst & Young LLP as AbbVie’s independent registered public accounting firm for 2021.
3.To vote on an advisory basis on the approval of executive compensation.
4.To approve the amended and restated 2013 incentive stock program.
5.To approve the amended and restated 2013 employee stock purchase plan for non-U.S. employees.
6.To vote on a management proposal to eliminate supermajority voting.
7.To consider any other matters that may properly come before the meeting, including two stockholder proposals, if presented during the meeting.
|
| 2020-03-23 |
股东大会：
将于2020-05-08召开股东大会
会议内容 ▼▲
- 1.To elect four directors to hold office until the 2023 Annual Meeting or until their successors are elected,
2.To ratify the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2020,
3.To vote on an advisory vote on the approval of executive compensation
4.To vote on a management proposal to eliminate supermajority voting
5.To transact such other business as may properly come before the meeting, including consideration of three stockholder proposals, if presented at the meeting.
|
| 2020-02-20 |
除权日：
美东时间 2020-04-14 每股派息1.18美元
|
| 2019-11-01 |
除权日：
美东时间 2020-01-14 每股派息1.18美元
|
| 2019-09-06 |
除权日：
美东时间 2019-10-11 每股派息1.07美元
|
| 2019-06-20 |
除权日：
美东时间 2019-07-12 每股派息1.07美元
|
| 2019-03-22 |
股东大会：
将于2019-05-03召开股东大会
会议内容 ▼▲
- 1.To elect three directors to hold office until the 2022 Annual Meeting or until their successors are elected,
2.To ratify the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2019,
3.To vote on an advisory vote on the approval of executive compensation,
4.To vote on a management proposal to eliminate supermajority voting,
5.To transact such other business as may properly come before the meeting, including consideration of three stockholder proposals, if presented at the meeting.
|
| 2019-02-21 |
除权日：
美东时间 2019-04-12 每股派息1.07美元
|
| 2018-11-02 |
除权日：
美东时间 2019-01-14 每股派息1.07美元
|
| 2018-09-07 |
除权日：
美东时间 2018-10-12 每股派息0.96美元
|
| 2018-06-14 |
除权日：
美东时间 2018-07-12 每股派息0.96美元
|
| 2018-03-19 |
股东大会：
将于2018-05-04召开股东大会
会议内容 ▼▲
- 1.To elect four directors to hold office until the 2021 Annual Meeting or until their successors are elected
2.To ratify the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2018
3.To vote on an advisory vote on the approval of executive compensation
4.To determine, in an advisory vote, whether the stockholder advisory vote to approve executive compensation should occur every one, two or three years
5.To vote on a management proposal regarding the annual election of directors
6.To vote on a management proposal to eliminate supermajority voting
7.To transact such other business as may properly come before the meeting, including consideration of three stockholder proposals, if presented at the meeting
|
| 2018-02-16 |
复牌提示：
2018-02-15 12:40:38 停牌，复牌日期 2018-02-15 13:00:39
|
| 2018-02-15 |
除权日：
美东时间 2018-04-12 每股派息0.96美元
|
| 2017-10-27 |
除权日：
美东时间 2018-01-11 每股派息0.71美元
|
| 2017-09-08 |
除权日：
美东时间 2017-10-12 每股派息0.64美元
|
| 2017-06-23 |
除权日：
美东时间 2017-07-12 每股派息0.64美元
|
| 2017-03-20 |
股东大会：
将于2017-05-05召开股东大会
会议内容 ▼▲
- 1.To elect 4 directors to hold office until the next Annual Meeting or until their successors are elected (Item 1),
2.To ratify the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2017 (Item 2),
3.To vote on an advisory vote on the approval of executive compensation (Item 3),
4.To vote on a management proposal regarding the annual election of directors (Item 4),
5.To transact such other business as may properly come before the meeting, including consideration of two stockholder proposals, if presented at the meeting (Items 5 and 6).
|
| 2017-02-16 |
除权日：
美东时间 2017-04-11 每股派息0.64美元
|
| 2016-10-28 |
除权日：
美东时间 2017-01-11 每股派息0.64美元
|
| 2016-09-09 |
除权日：
美东时间 2016-10-12 每股派息0.57美元
|
| 2016-06-16 |
除权日：
美东时间 2016-07-13 每股派息0.57美元
|
| 2016-03-21 |
股东大会：
将于2016-05-06召开股东大会
会议内容 ▼▲
- 1.To elect 3 directors to hold office until the next Annual Meeting or until their successors are elected (Item 1),
2.To ratify the appointment of Ernst & Young LLP as AbbVie's independent registered public accounting firm for 2016 (Item 2),
3.To vote on an advisory vote on the approval of executive compensation (Item 3),
4.To vote on a management proposal regarding the annual election of directors (Item 4),
5.To approve the material terms of the performance goals under the AbbVie Performance Incentive Plan (Item 5),
6.To transact such other business as may properly come before the meeting, including consideration of two stockholder proposals, if presented at the meeting (Items 6 and 7).
|
| 2016-02-18 |
除权日：
美东时间 2016-04-13 每股派息0.57美元
|
| 2015-10-20 |
除权日：
美东时间 2016-01-13 每股派息0.57美元
|
| 2015-09-11 |
除权日：
美东时间 2015-10-13 每股派息0.51美元
|
| 2015-07-24 |
除权日：
美东时间 2015-07-13 每股派息0.51美元
|
| 2015-02-19 |
除权日：
美东时间 2015-04-13 每股派息0.51美元
|
| 2014-10-20 |
除权日：
美东时间 2015-01-13 每股派息0.49美元
|
| 2014-09-19 |
除权日：
美东时间 2014-10-10 每股派息0.42美元
|
| 2014-06-19 |
除权日：
美东时间 2014-07-11 每股派息0.42美元
|
| 2014-02-20 |
除权日：
美东时间 2014-04-11 每股派息0.42美元
|
| 2013-12-12 |
除权日：
美东时间 2014-01-13 每股派息0.40美元
|
| 2013-09-19 |
除权日：
美东时间 2013-10-10 每股派息0.40美元
|
| 2013-06-20 |
除权日：
美东时间 2013-07-11 每股派息0.40美元
|
| 2013-02-15 |
除权日：
美东时间 2013-04-11 每股派息0.40美元
|
| 2013-01-04 |
除权日：
美东时间 2013-01-11 每股派息0.40美元
|